Covered recipient · General Payments record
WILLIAM RUSHING
General Payments · PY2018–2024
$2,678.34
- Reported across 161 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $210.46 | 15 |
| Education | $111.49 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $132.56 | 2 |
| Amgen Inc. | $87.84 | 5 |
| MAYNE PHARMA COMMERCIAL LLC | $43.18 | 3 |
| Organon LLC | $21.38 | 4 |
| Astellas Pharma US Inc | $19.87 | 1 |
| Hologic Sales and Service, LLC | $17.12 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $18.14 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116074531 | CMS |
| Amgen Inc. | $16.71 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116074538 | CMS |
| Amgen Inc. | $15.60 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116074544 | CMS |
| Amgen Inc. | $16.85 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116074552 | CMS |
| Amgen Inc. | $20.54 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116074558 | CMS |
| Astellas Pharma US Inc | $19.87 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139407807 | CMS |
| Hologic Sales and Service, LLC | $17.12 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1084868249 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $11.21 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154698403 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $14.18 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154698407 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $17.79 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154698405 | CMS |
| Organon Llc | $4.73 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136303228 | CMS |
| Organon Llc | $1.31 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136303232 | CMS |
| Organon Llc | $11.84 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136303234 | CMS |
| Organon Llc | $3.50 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136303230 | CMS |
| Teva Pharmaceuticals USA, Inc. | $21.07 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151565012 | CMS |
| Teva Pharmaceuticals USA, Inc. | $111.49 | 05/23/2024 | Education | Undisputed | 01/23/2026 | 1151565042 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.